These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 9949762)

  • 21. Tramadol pharmacokinetics and its possible interactions with cyclooxygenase 2-selective nonsteroidal anti-inflammatory drugs.
    Punwani NG
    Clin Pharmacol Ther; 2004 Apr; 75(4):363-5. PubMed ID: 15060515
    [No Abstract]   [Full Text] [Related]  

  • 22. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs.
    Zhao SZ; Wentworth C; Burke TA; Makuch RW
    Pharmacoepidemiol Drug Saf; 2004 May; 13(5):277-87. PubMed ID: 15133778
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Selective cox-2 inhibitors. Better tolerance than NSAID plus antacid].
    MMW Fortschr Med; 2004 Apr; 146(15):66. PubMed ID: 15373027
    [No Abstract]   [Full Text] [Related]  

  • 24. [Pharma-clinics. The drug of the month. Celecoxib (Celebrex)].
    Scheen AJ
    Rev Med Liege; 2001 Jan; 56(1):53-5. PubMed ID: 11256140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective cyclooxygenase-2 inhibitors for the treatment of arthritis.
    Fung HB; Kirschenbaum HL
    Clin Ther; 1999 Jul; 21(7):1131-57. PubMed ID: 10463513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG;
    Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Gastroduodenal tolerance of celecoxib (celebrex) in patients with osteoarthrosis: an endoscopic evaluation].
    Karateev AE
    Ter Arkh; 2001; 73(5):63-4. PubMed ID: 11517755
    [No Abstract]   [Full Text] [Related]  

  • 28. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice.
    Wolfe F; Michaud K; Burke TA; Zhao SZ
    J Rheumatol; 2004 Feb; 31(2):355-8. PubMed ID: 14760808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis.
    Eisen GM; Goldstein JL; Hanna DB; Rublee DA
    Aliment Pharmacol Ther; 2005 Mar; 21(5):591-8. PubMed ID: 15740543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Celecoxib approved as NSAID with some concessions on class warning.
    Miller JL
    Am J Health Syst Pharm; 1999 Mar; 56(5):403. PubMed ID: 10096694
    [No Abstract]   [Full Text] [Related]  

  • 31. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Symptomatic therapy of arthrosis and rheumatoid arthritis. Who will benefit from Coxib?].
    MMW Fortschr Med; 2002 Apr; 144(14):53. PubMed ID: 12014284
    [No Abstract]   [Full Text] [Related]  

  • 33. COX-2 inhibitors.
    Crowther CL
    Lippincotts Prim Care Pract; 1999; 3(4):394-6. PubMed ID: 10624270
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical profiles of celecoxib and rofecoxib in the rheumatic diseases.
    Gibofsky A
    J Hypertens Suppl; 2002 Sep; 20(6):S25-30. PubMed ID: 12683424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Alleviating pain and preventing inflammation with selective COX-2 inhibitors. Prescribing with confidence in the future].
    MMW Fortschr Med; 2005 Mar; 147(9):12. PubMed ID: 15794346
    [No Abstract]   [Full Text] [Related]  

  • 36. [Current EULAR data on valdecoxib. New study results of gastrointestinal safety and "cost effectiveness"].
    Kellner H
    Krankenpfl J; 2004; 42(5-6):185. PubMed ID: 15527245
    [No Abstract]   [Full Text] [Related]  

  • 37. Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Problems compromise review's validity.
    Juni P; Sterchi R; Dieppe P
    BMJ; 2003 Feb; 326(7384):334; author reply 334. PubMed ID: 12574052
    [No Abstract]   [Full Text] [Related]  

  • 38. COX 2-selective NSAIDs: biology, promises, and concerns.
    Mandell BF
    Cleve Clin J Med; 1999 May; 66(5):285-92. PubMed ID: 10330781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective COX-2 inhibitors.
    Pasero C; McCaffery M
    Am J Nurs; 2001 Apr; 101(4):55-6. PubMed ID: 11301685
    [No Abstract]   [Full Text] [Related]  

  • 40. Treatment of rheumatoid arthritis and osteoarthritis with COX-2-selective inhibitors: a managed care perspective.
    Hochberg MC
    Am J Manag Care; 2002 Nov; 8(17 Suppl):S502-17. PubMed ID: 12458820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.